Pall Puts Down $185 Million for ATMI

!--h2>

The deal is expected to close in Pall’s fiscal third quarter. “This acquisition immediately strengthens our offering and broadens our already extensive portfolio of advanced solutions for biopharmaceutical customers,” said Larry Kingsley, Pall’s chairman and CEO. “We are very happy to have Pall as the new owner of this business, and believe the fit and their capabilities will accelerate its growth and provide great support to our customers” added Doug Neugold, ATMI’s CEO.

The move exemplifies the major current bioprocess trend toward single-use instruments. Earlier this year, Pall introduced the XRS 20 bioreactor system, a new bioreactor that incorporates a single-use Allegro™ 3D biocontainer. The product is designed for cultivation of mammalian cells in suspension culture and is suitable for applications ranging from general life sciences research to seed train operations and full GMP production at the 2-to-20 liter scale, according to Pall officials.